NUVB•benzinga•
Nuvation Bio To Present Addl Results From TRUST-I And TRUST-II, Pivotal Phase 2 Clinical Studies On Efficacy And Safety Of Taletrectinib For Advanced ROS1+ NSCLC Treatment At ASCO 2025 Annual Meeting
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 21, 2025 by benzinga